Reaction

Mantle Cell Lymphoma Refractory reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 63 reports · 1 co-occurring drugs

As of the last recalculation, Mantle Cell Lymphoma Refractory appears in 63 FAERS reports alongside 1 co-occurring drug terms. The strongest observed disproportionality signal is OBINUTUZUMAB (PRR 328.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Obinutuzumab	13	328.7	329.0

Related reactions

Drug Ineffective
Off Label Use
Death
Nausea
Fatigue

Data source: openFDA FAERS. See the OpenPV methodology and limitations.